MedTrace Logo

Safety, Blood Levels and Effects of MGB-BP-3

NCT02518607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-03-17

No results posted yet for this study

Summary

This study is to assess the safety and tolerability aspects of oral MGB-BP-3, a treatment for Clostridium difficile infections.

Conditions

  • Healthy

Interventions

DRUG

MGB-BP-3

Treatment of CDI

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Hammersmith Medicines Research

    collaborator OTHER

  • Innovate UK

    collaborator OTHER_GOV

  • Cambridge Regulatory Services

    collaborator UNKNOWN

  • Phases Clinical Research Limited

    collaborator UNKNOWN

  • Synlab Services

    collaborator UNKNOWN

  • Viapath

    collaborator UNKNOWN

  • Analytical Services International Limited

    collaborator UNKNOWN

  • MGB Biopharma Limited

    lead INDUSTRY

Principal Investigators

  • Malcolm Boyce, Various · HMR London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-11-30
Completion
2015-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518607 on ClinicalTrials.gov